# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Jo Walton downgrades GSK (NYSE:GSK) from Buy to Neutral.
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug. iTeos and GSK en...
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying afte...
- Reuters
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluate-potential-risk-neural-tube-bi...
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...